Chronic Urticaria Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's "Chronic Urticaria Pipeline Insight, 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Urticaria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Dive into DelveInsight's comprehensive report today! @ https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Urticaria Pipeline Report

* On January 22, 2026- Jasper Therapeutics Inc . announced a phase 1B/2A trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, and other pharmacodynamic (PD) parameters (such as effects on mast cells (MC), serum tryptase levels, and on allergic skin reactivity) will be investigated.
* On January 21, 2026- Evommune Inc . conducted a study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
* On January 13, 2026- Novartis Pharmaceuticals initiated a clinical study was designed to evaluate the pharmacokinetics, safety and efficacy of ligelizumab in children from 12 to < 18 years of age, with chronic spontaneous urticaria (CSU). The participants were treated with ligelizumab as an add-on therapy to approved doses of H1 antihistamines (H1AH) following the guideline on treatment of CSU.
* On January 12, 2026- Celldex Therapeutics announced Phase 3 study is to assess the activity and safety of barzolvolimab compared to placebo in participants with cold induced urticaria or symptomatic dermographism who remain symptomatic despite the use of H1-antihistamines.
* On January 08, 2026- Blueprint Medicines Corporation announced a study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).
* DelveInsight's Chronic Urticaria pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Chronic Urticaria treatment.
* The leading Chronic Urticaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical , and others.
* Promising Chronic Urticaria Pipeline Therapies such as Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine , and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chronic Urticaria Treatment Drugs [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Chronic Urticaria Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Chronic Urticaria Pipeline Report also highlights the unmet needs with respect to Chronic Urticaria.

Chronic Urticaria Overview

Chronic urticaria is a skin condition characterized by the repeated appearance of hives (raised, itchy welts) and/or angioedema (deeper swelling of the skin) that lasts for six weeks or longer. The symptoms may occur daily or intermittently and can significantly affect quality of life. In most cases, chronic urticaria is idiopathic, meaning the exact cause is unknown. When no clear trigger is identified, it is referred to as chronic spontaneous urticaria (CSU). In some individuals, the condition may be linked to autoimmune reactions, where the immune system mistakenly activates mast cells, leading to the release of histamine and other inflammatory mediators.

Chronic Urticaria Emerging Drugs Profile

* CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd

CMAB007 is a recombinant humanized anti-IgE monoclonal antibody developed by Taizhou Mabtech Pharmaceutical Co., Ltd., a subsidiary of Mabpharm Limited. Approved in China in May 2023, it is the first domestically produced therapeutic antibody for allergic asthma. CMAB007 is also undergoing Phase III clinical trials for chronic spontaneous urticaria in patients unresponsive to H1 antihistamines. As an omalizumab biosimilar, it targets IgE-mediated allergic diseases and has been included in China's national health insurance catalogue, facilitating widespread adoption across healthcare institutions. Currently, the drug is in Phase III stage of its development for the treatment of Chronic Urticaria.

* Povorcitinib - Incyte Corporation

Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for prurigo nodularis (PN). Phase II studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing. Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase III clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.

* Briquilimab: Jasper Therapeutics

Briquilimab (JSP191) is an unconjugated, aglycosylated, anti-c-Kit antibody that functionally blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF). The interaction of SCF and c-Kit is required for mast cells to survive. By blocking SCF from binding to c-Kit and disrupting the critical survival signal, briquilimab causes mast cells to undergo orderly cell death. For mast cell-driven diseases such as chronic urticaria, this removes the underlying source of the inflammatory response. In low-to-intermediate risk MDS, briquilimab blocks critical cell survival signals, depleting Kit-expressing MDS cells. For stem cell transplant, briquilimab blocks the ability of stem cells to recover from low intensity radiation, thereby opening the specific niches in the bone marrow for donor or gene-corrected hematopoietic stem cells to engraft. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.

Explore groundbreaking therapies and clinical trials in the Chronic Urticaria Pipeline @ New Chronic Urticaria Drugs [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Chronic Urticaria Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Urticaria with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Urticaria Treatment.
* Chronic Urticaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Chronic Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Urticaria market

Chronic Urticaria Companies

Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical , and others.

Chronic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Chronic Urticaria Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Unveil the future of Chronic Urticaria Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Urticaria Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Chronic Urticaria Pipeline Report

* Coverage- Global
* Chronic Urticaria Companies- Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical , and others.
* Chronic Urticaria Pipeline Therapies- Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine , and others.
* Chronic Urticaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chronic Urticaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Chronic Urticaria Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Urticaria Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Chronic Urticaria: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chronic Urticaria - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd
* Mid Stage Products (Phase II)
* Povorcitinib - Incyte Corporation
* Early Stage Products (Phase I)
* Briquilimab: Jasper Therapeutics
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Chronic Urticaria Key Companies
* Chronic Urticaria Key Products
* Chronic Urticaria - Unmet Needs
* Chronic Urticaria - Market Drivers and Barriers
* Chronic Urticaria - Future Perspectives and Conclusion
* Chronic Urticaria Analyst Views
* Chronic Urticaria Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-urticaria-clinical-trial-pipeline-gains-momentum-20-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.